Company introduction
GDBspace is a chemical space-based drug discovery engine – its unique technology applies the chemical space theory to identify small molecules (incl. peptides and peptidomimetics) of interests in a precise and time-efficient manner – hence de-risking projects, increasing success rates, and significantly reducing time and costs.
The Space Peptides laboratory arm is specialized in peptide manufacturing, as well as in vitro / in vivo validation of the molecules of interests. For more information, see: http://spacepeptides.com
Company Locations
Our Locations
Research Center, Messeturm Basel,
Switzerland
R&D collaboration with Uni. Bern,
Switzerland
Cell and animals laboratories in Xiamen, China
Non-GMP and GMP standard pilot plant in Xiamen, China (capacity 50kg/year)
API Factory in Jiangsu, China
(capacity 1100kg/year, in progress）
Satellite Office, Boston, USA
Satellite Office, San Francisco, USA
Core Team
Dr. Runze He
Dr. Jingwen Shi
Co-founded GDBspace when envisioning its huge potential. Management consultant for pharmaceuticals (clients include Roche, Novartis, Boehringer Ingelheim, etc) and private equity investments. Angel investor in Abionic, Wildbiene. Board member of Space Peptides, where building successful partnerships for the company.
PhD from Karolinska Institute; Visiting scholar at Max-Planck Institute. Business Administration from Notre Dame, USA. Publications in Nature Nanotechnology, ACS, etc.
Dr. Sacha Javor
Computational chemist and expertise in peptide chemistry. Participated in innovation management with SITEM-Insel.
Postdoc at Scripps Institute, USA. PhD from University Bern, Switzerland.
Dr. Kapila Gunasekera
Dr. Kapila Gunasekera has more than 20 years of computational chemistry / biology experience in the pharmaceutical and life science industry, with numerous publications in leading peer-reviewed journals. He has a PhD in Molecular Biology at the University of Bern.
Advisory Board
Prof. Jean-Louis Reymond
Worldwide renowned for its research on chemical space.
Professor in chemistry, Bern University. Previously assistant professor at Scripps Research Institute.
Associate member of the Swiss National Center of Competence in Research (NCCR) Chemical Biology. Associate editor of Chem. Comm.
Published 200+ articles in high impact journals, funded by Swiss National Science Foundation, European Horizon2020 etc., 3 spin-off companies.
Prof. Wenjing Hong
Prof. Hong focus on single-molecule scale electronics and instrumental engineering. He is a Professor of Chemical Engineering in Xiamen University, China. Previously, leader of the molecular electronics research in the group of Prof. Dr. Thomas Wandlowski in University of Bern, Switzerland.
Published 60+ peer-reviewed papers in top journals of chemistry.
Dr. Hongming Chen
After working as a postdoctoral fellow in computational chemistry in Bayer Pharma Research Center in Wuppertal, Germany, Hongming Chen joined AstraZeneca R&D Mölndal, Sweden, in 2001. He has been focusing on QSAR modeling and cheminformatics and has delivered various predictive tools and computational chemistry support to the AstraZeneca Compound Collection Enhancement and Predictive Chemistry initiatives, as well as to numerous early drug discovery projects. He has authored/coauthored 30 scientific papers and three book chapters.
Hongming Chen studied polymer material engineering in Northwestern Polytechnical University, China, and obtained his PhD in computational chemistry in 1998 from the Institute of Chemical Metallurgy, Chinese Academy of Sciences.
Company history
Our history
Technology transfer from Prof. Reymond’s group at Uni Bern, Switzerland
Peptide synthesis process development and mid-scale manufacturing pilot plant (capacity 50kg/yr)
Chemical space theory applied to drug discovery
Case study: Covid-19 peptide fusion inhibitor
Laboratories for in vitro & in vivo tox, PK studies
Opening ceremony of large-scale peptide API manufacture plant (capacity 1100kg/yr)
Market Proof-of Concept established with leading brands in key markets
